AMSBIO Offers Adipose & Placental Stem Cell-Derived Exosomes As Tools for Regenerative Medicine Work

AMSBIO has announced its launch of a new range of human exosomes for the regenerative medicine tools and technologies market. Derived from placental and adipose-derived stem cells, to ensure consistent high quality, these new products are ideally suited for research involving wound healing, stem cell differentiation, and tissue regeneration. Because few transplanted cells persist in vivo, the beneficial effects of cell therapy may lie in the secreted factors being the active component of this treatment. A key part of paracrine secretion is exosomes, which are membraned vesicles that are stored intracellularly in endosomal compartments and are secreted when these structures fuse with the cell plasma membrane. Exosomes often contain protein, DNA, and RNA, thus making them an attractive vector of paracrine signals delivered by stem cells. Exosomes may also be "loaded" with pre-determined proteins and nucleic acid to achieve a desired effect. Exosomes can be stored as an "off-the-shelf" product having the potential for circumventing many of the limitations of viable cells for therapeutic applications in regenerative medicine. In vitro, exosomes from pre-adipocytes stimulate cell proliferation in a wound-healing model. In vivo, adipose-graft-derived exosomes have been shown to be a promising tool for skin repair and remodeling. All cells have been screened negative for HIV-1, HIV-2, HTLC-1, HTLV-2, Hep-B, Hep-C. All isolated and concentrated exosomes undergo quality control including particle mean diameter, protein concentration, RNA concentration and concentration of particles/ml. AMSBIO’s mission is to be a profitable premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products, and medicines.
Login Or Register To Read Full Story